Brazil's ANVISA to Reevaluate Ban on E-Cigarettes in 2022

Dec.01.2023
Brazil's ANVISA to Reevaluate Ban on E-Cigarettes in 2022
Brazilian health authorities are set to reconsider the ban on e-cigarettes, despite their widespread illegal presence in the market.

According to a recent report by Veja, the Brazilian National Health Surveillance Agency (ANVISA) is set to hold a public meeting on December 1, 2022 to discuss the ban on e-cigarettes that has been in effect since 2009. Despite the ban, e-cigarettes continue to be widely available in the market in Brazil. A survey conducted by Ipec in 2022 revealed that approximately 2.2 million adults in Brazil regularly consume e-cigarettes, making this market entirely illegal.


Brazilian Senator Soraya Thronicke introduced a bill in October aimed at regulating the production, import, export, sale, supervision, and advertising of e-cigarettes in Brazil. During the defense debate, she emphasized that the sale of e-cigarettes (vapes) in Brazil is currently unregulated, putting consumers at risk as they are unaware of the products or substances they are inhaling. "What risks are these people facing? Why are we indifferent to this serious issue, while consumption has already reached nearly six million adults?" she questioned.


Senator Tronik also cited the losses resulting from tax evasion. "From an economic perspective, the import and sale of e-cigarettes operate on the fringes of the tax system, leading to significant tax losses," she emphasized. According to a study by the Minas Gerais State Industry Federation (FIEMG), the potential market for e-cigarettes could reach 7.5 billion Brazilian reals annually. Considering only imports, the average annual federal tax revenue could reach 2.2 billion Brazilian reals.


Dr. Joelmir Silva, a full-time professor at the Olynda Medical School, emphasized the importance of regulations, stating, "Without regulations, it is impossible to know what is being sold. The lack of control over products, especially those containing counterfeit substances, can pose a greater risk to health. The lack of regulations regarding product composition and ingredient limits is another issue of concern.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 Former DHS Spokesperson Analyzes CBP’s $175 Million Illegal Vape Seizure
Former DHS Spokesperson Analyzes CBP’s $175 Million Illegal Vape Seizure
The Washington Examiner published an opinion article by Tricia McLaughlin, former Assistant Secretary for Public Affairs and spokesperson at the U.S. Department of Homeland Security, arguing that the Trump administration is strengthening enforcement against illegal vape supply chains through the FDA, CBP, and DHS.
Regulations
May.25
Nicotine Pouches Lead U.S. Tobacco Growth as Vape Sales Decline
Nicotine Pouches Lead U.S. Tobacco Growth as Vape Sales Decline
New convenience store industry data show nicotine pouches have become the primary growth driver in the tobacco category, with oral nicotine sales rising nearly 30% over the past year while vape sales declined.
Business
Jun.05
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
British American Tobacco (BAT) subsidiary Vuse Alto has recently adjusted its price tiers in U.S. convenience store channels, leveraging low-cost device kits and pod promotions to reinforce its positioning in the mid-priced closed-system e-cigarette market.
Jun.17
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
KT&G disclosed in a regulatory filing on Friday that Capital Research and Management Company, the investment management arm of Capital Group, had acquired a 5.61% stake through purchases made on April 22 and May 4. The move places Capital Group among KT&G’s prominent foreign shareholders, alongside BlackRock, First Eagle Investment Management and Singapore’s sovereign wealth fund GIC.
May.08 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy’s Competition and Market Authority (AGCM) has fined Philip Morris Italia €7 million, finding that the company’s use of “smoke-free future” and related claims in promoting products such as IQOS, VEEV and ZYN could mislead consumers.
Jun.16